CTVA vs ZTS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ZTS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CTVA and ZTS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CTVA and ZTS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Corteva is one of the largest agricultural input companies in the world, formed in 2019 when DowDuPont spun off its agriculture business. The company operates two main segments. Seed develops and sells genetically improved corn, soybean, canola, and other crop seeds. Crop Protection develops and sells herbicides, insecticides, fungicides, and biological products to protect crops from weeds, insects, and diseases.

Full CTVA guide

Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). Spun out of Pfizer in 2013, it holds leading positions across dermatology, parasiticides, pain, vaccines, and other categories, with well-known franchises such as Apoquel and Cytopoint for pet itch and allergic skin conditions, the Simparica line of parasiticides, and Librela for osteoarthritis pain in dogs. Companion animal products, driven by the long-run humanization of pets and rising spending on their care, have become the larger and faster-growing part of the business, while livestock provides a more staple, protein-demand-linked base. Zoetis sells through veterinarians in the United States and internationally, invests heavily in research and development to sustain its innovation pipeline, and benefits from patents, brand loyalty, and deep vet relationships. Headquartered in Parsippany, New Jersey, it is widely viewed as a defensive-growth leader on the structural trend of people spending more on animal health, though it faces cyclical pet-visit softness, pricing pressure, and rising competition.

Full ZTS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CTVA drivers: Seed technology pipeline; Biological products growth.
• ZTS drivers: Leader in a structurally growing market; Innovation-driven franchises and pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Commodity crop price cycles affect farmer purchasing power and Corteva revenue. For ZTS, zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CTVA if you believe its drivers more; ZTS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CTVA and ZTS guides.

CTVA. Corteva trades at a premium to traditional chemicals and materials peers reflecting the pure-play agricultural input exposure, the durable seed franchise, and the biologicals growth story. The multiple compresses during commodity crop downturns when farmer income weakens.

ZTS. Zoetis is valued as a high-quality, defensive-growth compounder, so it often trades at a premium price-to-earnings multiple relative to the broad market. In early 2026 it trimmed full-year guidance, citing softer pet-visit trends, price-sensitive pet owners, and competition, which pressured the stock. Livestock and international growth partly offset soft US companion-animal demand. Figures are approximate and change with each quarter and with currency movements; verify current numbers before relying on them.

Headline figures (approximate, early 2026): CTVA shows revenue (ttm) ~$17 billion, operating margin ~13%, net income (ttm) ~$1.5 billion, eps (ttm) ~$2.20; ZTS shows revenue (2026 guidance) ~$9.7 billion to $10.0 billion, q1 2026 revenue ~$2.3 billion, up ~3% year over year, adjusted eps (2026 guidance) ~$6.85 to $7.00, business mix companion animal (larger, faster-growing) plus livestock.

CTVA and ZTS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CTVA and ZTS exposure against your real portfolio. It is not an investment adviser.